When ignorance is bliss: Intentional agnosticism in drug approval

Area of Science:

• Health policy
• Pharmaceutical regulation
• Clinical trial design

Background:

• Developed nations' health agencies rely on randomized controlled trials (RCTs) for drug approval.
• RCTs frequently exclude diverse patient populations, leading to drug approvals based on limited treatment response data.
• Some agencies have not mandated broader inclusion in trials, remaining uninformed about specific populations' drug responses.

Purpose of the Study:

• To explore the decision-making process of health agencies regarding the exclusion of populations from drug approval trials.
• To introduce a novel mechanism explaining intentional agency agnosticism towards specific populations' treatment effects.
• To investigate how prescription rate ambiguity influences population exclusion in drug trials.

Main Methods:

• Introduction of a theoretical mechanism for health agency agnosticism in drug approval.
• Analysis of how ambiguity in on-label and off-label prescription rates impacts trial inclusion decisions.
• Exploration of factors beyond trial necessity and cost that may drive population exclusion.

Main Results:

• A novel mechanism is presented for health agencies intentionally remaining agnostic about certain populations' drug responses.
• Ambiguity surrounding on-label and off-label prescription rates can incentivize the exclusion of populations from drug trials.
• This exclusion can occur even when trial necessity and cost are not primary concerns.

Conclusions:

• Health agencies may opt for intentional ignorance regarding specific populations' drug efficacy.
• Uncertainty in prescription data can be a driving factor for excluding populations in drug approval processes.
• The findings highlight a potential systemic issue in drug approval that may not be driven by traditional cost or necessity factors.